This profound prognostic discrepancy led the World Health Organization in its 2016 Classification of CNS Tumors to subdivide diffuse gliomas into two distinct categories: those with IDH mutations (IDH-mutant) and those without (IDH wild-type or IDHwt) [11]. This evidence concerns the gene IDH2 and central nervous system neoplasm.